{"success":true,"data":{"pressRelease":{"id":"134302","rtpr_id":"nGNX3HlDlq","ticker":"AVXL","exchange":"NASDAQ","all_tickers":["AVXL"],"title":"Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement","author":"Globe Newswire","published_at":"2026-09-02T20:00:00.095Z","article_body":"NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.\n(“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage\nbiopharmaceutical company focused on developing innovative treatments for\ncentral nervous system (“CNS”) diseases with high unmet medical needs,\ntoday announced that it has received confirmation from The Nasdaq Stock Market\nLLC (“Nasdaq”) that the Company has regained compliance with Nasdaq\nListing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all\nrequired periodic filings with the Securities and Exchange Commission\n(“SEC”).\n\nOn August 28, 2026, the Company filed its outstanding Form 10-Q filings for\nthe second and third fiscal quarters of 2026 with the SEC. The Company is now\nin compliance with all Nasdaq listing standards, and its common stock will\ncontinue to trade on the Nasdaq Global Select Market under the ticker \"AVXL.\"\n\nAbout Anavex Life Sciences Corp.\n\nAnavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage\nbiopharmaceutical company engaged in the development of novel therapeutics for\nthe treatment of central nervous system (“CNS”) diseases with high unmet\nmedical need. Further information is available at www.anavex.com.\n\nForward-Looking Statements\n\nStatements in this press release that are not strictly historical in nature\nare forward-looking statements. These statements include, but are not limited\nto, statements relating to the Company’s ability to continue trading on the\nNasdaq Global Select Market. These statements are based on current information\nand expectations and involve a number of risks and uncertainties. Actual\nevents or results may differ materially from those projected in any of such\nforward-looking statements due to various factors, including, but not limited\nto, risks related to the Company’s ability to maintain compliance with the\nNasdaq Listing Rules; and other risks and uncertainties set forth in the\nCompany’s Annual Report on Form 10-K for the fiscal year ended September 30,\n2025, filed with the Securities and Exchange Commission (“SEC”) on\nNovember 25, 2025, the Company’s Quarterly Report on Form 10-Q for the\nquarterly period ended December 31, 2025, filed with the SEC on February 9,\n2026, the Company’s Form 10-K/A for the fiscal year ended September 30,\n2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for\nthe quarterly period ended December 31, 2025, filed with the SEC on August 28,\n2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period\nended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s\nQuarterly Report on Form 10-Q for the quarterly period ended June 30, 2026,\nfiled with the SEC on August 28, 2026, and subsequent filings and furnishings\nwith the SEC. Readers are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement and Anavex Life Sciences Corp. undertakes no obligation to revise or\nupdate this press release to reflect events or circumstances after the date\nhereof except as required by law.\n\nInvestor Relations & Media Contact:\n\nSCR Partners, LLC\nAlex Arzeno\nTel: 203-550-3972\nEmail: alex@scr-ir.com \n\nTripp Sullivan\nTel: 615-942-7077\nEmail: tsullivan@scr-ir.com \n\nCompany Contact:\n\nSandra Boenisch\nPrincipal Financial Officer\nAnavex Life Sciences Corp.\nTel: 1-844-689-3939\nEmail: ir@anavexcorp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b0f858f-4f7f-4f50-b691-a25307283fb5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3HlDlq","title":"Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement","author":"Globe Newswire","ticker":"AVXL","created":"2026-09-02T20:00:00.095Z","tickers":["AVXL"],"exchange":"NASDAQ","article_body":"NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.\n(“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage\nbiopharmaceutical company focused on developing innovative treatments for\ncentral nervous system (“CNS”) diseases with high unmet medical needs,\ntoday announced that it has received confirmation from The Nasdaq Stock Market\nLLC (“Nasdaq”) that the Company has regained compliance with Nasdaq\nListing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all\nrequired periodic filings with the Securities and Exchange Commission\n(“SEC”).\n\nOn August 28, 2026, the Company filed its outstanding Form 10-Q filings for\nthe second and third fiscal quarters of 2026 with the SEC. The Company is now\nin compliance with all Nasdaq listing standards, and its common stock will\ncontinue to trade on the Nasdaq Global Select Market under the ticker \"AVXL.\"\n\nAbout Anavex Life Sciences Corp.\n\nAnavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage\nbiopharmaceutical company engaged in the development of novel therapeutics for\nthe treatment of central nervous system (“CNS”) diseases with high unmet\nmedical need. Further information is available at www.anavex.com.\n\nForward-Looking Statements\n\nStatements in this press release that are not strictly historical in nature\nare forward-looking statements. These statements include, but are not limited\nto, statements relating to the Company’s ability to continue trading on the\nNasdaq Global Select Market. These statements are based on current information\nand expectations and involve a number of risks and uncertainties. Actual\nevents or results may differ materially from those projected in any of such\nforward-looking statements due to various factors, including, but not limited\nto, risks related to the Company’s ability to maintain compliance with the\nNasdaq Listing Rules; and other risks and uncertainties set forth in the\nCompany’s Annual Report on Form 10-K for the fiscal year ended September 30,\n2025, filed with the Securities and Exchange Commission (“SEC”) on\nNovember 25, 2025, the Company’s Quarterly Report on Form 10-Q for the\nquarterly period ended December 31, 2025, filed with the SEC on February 9,\n2026, the Company’s Form 10-K/A for the fiscal year ended September 30,\n2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for\nthe quarterly period ended December 31, 2025, filed with the SEC on August 28,\n2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period\nended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s\nQuarterly Report on Form 10-Q for the quarterly period ended June 30, 2026,\nfiled with the SEC on August 28, 2026, and subsequent filings and furnishings\nwith the SEC. Readers are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement and Anavex Life Sciences Corp. undertakes no obligation to revise or\nupdate this press release to reflect events or circumstances after the date\nhereof except as required by law.\n\nInvestor Relations & Media Contact:\n\nSCR Partners, LLC\nAlex Arzeno\nTel: 203-550-3972\nEmail: alex@scr-ir.com \n\nTripp Sullivan\nTel: 615-942-7077\nEmail: tsullivan@scr-ir.com \n\nCompany Contact:\n\nSandra Boenisch\nPrincipal Financial Officer\nAnavex Life Sciences Corp.\nTel: 1-844-689-3939\nEmail: ir@anavexcorp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b0f858f-4f7f-4f50-b691-a25307283fb5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T20:00:00.134894583Z","server_sent_at_ms":1788379200134},"received_at":"2026-09-02T20:00:00.220Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355471/29248/en/anavex-life-sciences-regains-compliance-with-nasdaq-periodic-filing-requirement.html"},"analysis":{"id":"123197","press_release_id":"134302","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Company was delinquent on periodic filings, requiring two Form 10-Q catch-up filings for fiscal Q2 and Q3 2026","Filed amended 10-K (FY2025) and amended 10-Q (Q1 2026) in August 2026, suggesting prior reporting or accounting issues","Forward-looking statements explicitly flag ongoing risk of maintaining Nasdaq Listing Rule compliance"],"eventType":"regulatory","narrative":"Anavex Life Sciences has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to file all required periodic reports with the SEC.\n\nThe clinical-stage CNS biotech filed its outstanding Form 10-Qs for the second and third fiscal quarters of 2026 on August 28, 2026, along with an amended Form 10-K and an amended Form 10-Q, and its stock continues trading on the Nasdaq Global Select Market under ticker AVXL.\n\nWhile the delisting overhang is now resolved, the need for catch-up filings and amendments to prior reports points to reporting-process weaknesses worth monitoring.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Delisting overhang cleared for AVXL after late-filing catch-up, but the amendment trail warrants a watch on reporting quality."},"keyFigures":{"customDimensions":{"listing_rule":"Nasdaq Listing Rule 5250(c)(1)","listing_status":"continues trading on Nasdaq Global Select Market as AVXL","amendments_filed":["Form 10-K/A for fiscal year ended September 30, 2025","Form 10-Q/A for quarterly period ended December 31, 2025"],"late_filings_cured":"Form 10-Q for fiscal Q2 2026 and Form 10-Q for fiscal Q3 2026","catch_up_filing_date":"2026-08-28","compliance_confirmed":"2026-09-02"}},"namedEntities":{"people":[{"name":"Sandra Boenisch","role":"Principal Financial Officer, Anavex Life Sciences"},{"name":"Alex Arzeno","role":"Investor Relations contact, SCR Partners"},{"name":"Tripp Sullivan","role":"Investor Relations contact, SCR Partners"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"filer/issuer"},{"name":"The Nasdaq Stock Market LLC","relationship":"listing exchange"},{"name":"Securities and Exchange Commission","relationship":"regulator"},{"name":"SCR Partners, LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The issuer regained Nasdaq listing compliance after filing two overdue Form 10-Qs, removing a delisting overhang for a small clinical-stage biotech. It is an administrative resolution rather than fundamental business news, but the delinquency and amended filings it cures are worth noting."},"tickerRelevance":{"others":[],"primary":"AVXL"},"globalImportance":14,"audienceRelevance":18,"eventTypeSecondary":["late_filing"],"importanceComponents":{"eventClass":"regulatory-filing-compliance","tickerTier":"small-cap","eventGravity":"listing-compliance-restored","issuerAuthored":true,"retailFavoriteBoost":"clinical-stage biotech with retail following"}},"event_type":"regulatory","event_type_secondary":["late_filing"],"sentiment":"bullish","material_impact_score":2,"narrative":"Anavex Life Sciences has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to file all required periodic reports with the SEC.\n\nThe clinical-stage CNS biotech filed its outstanding Form 10-Qs for the second and third fiscal quarters of 2026 on August 28, 2026, along with an amended Form 10-K and an amended Form 10-Q, and its stock continues trading on the Nasdaq Global Select Market under ticker AVXL.\n\nWhile the delisting overhang is now resolved, the need for catch-up filings and amendments to prior reports points to reporting-process weaknesses worth monitoring.","key_figures":{"customDimensions":{"listing_rule":"Nasdaq Listing Rule 5250(c)(1)","listing_status":"continues trading on Nasdaq Global Select Market as AVXL","amendments_filed":["Form 10-K/A for fiscal year ended September 30, 2025","Form 10-Q/A for quarterly period ended December 31, 2025"],"late_filings_cured":"Form 10-Q for fiscal Q2 2026 and Form 10-Q for fiscal Q3 2026","catch_up_filing_date":"2026-08-28","compliance_confirmed":"2026-09-02"}},"named_entities":{"people":[{"name":"Sandra Boenisch","role":"Principal Financial Officer, Anavex Life Sciences"},{"name":"Alex Arzeno","role":"Investor Relations contact, SCR Partners"},{"name":"Tripp Sullivan","role":"Investor Relations contact, SCR Partners"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"filer/issuer"},{"name":"The Nasdaq Stock Market LLC","relationship":"listing exchange"},{"name":"Securities and Exchange Commission","relationship":"regulator"},{"name":"SCR Partners, LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T20:01:02.068Z","global_importance":14,"audience_relevance":18,"importance_components":{"eventClass":"regulatory-filing-compliance","tickerTier":"small-cap","eventGravity":"listing-compliance-restored","issuerAuthored":true,"retailFavoriteBoost":"clinical-stage biotech with retail following"}},"durationMs":61831,"modelName":"glm-4.7"}}